Michael Garnreiter Sells 1,000 Shares of Axon Enterprise, Inc. (NASDAQ:AXON) Stock

Axon Enterprise, Inc. (NASDAQ:AXON) Director Michael Garnreiter sold 1,000 shares of the stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $437.98, for a total transaction of $437,980.00. Following the sale, the director now directly owns 26,259 shares of the company’s stock, valued at $11,500,916.82. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Michael Garnreiter also recently made the following trade(s):

• On Monday, September 16th, Michael Garnreiter sold 1,000 shares of Axon Enterprise stock. The stock was sold at an average price of $380.99, for a total value of $380,990.00.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON opened at $433.83 on Thursday. The business has a fifty day moving average price of $385.93 and a 200-day moving average price of $330.03. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52. The company has a market capitalization of $32.78 billion, a PE ratio of 114.47, a PEG ratio of 11.74 and a beta of 0.94. Axon Enterprise, Inc. has a 1-year low of $199.29 and a 1-year high of $440.89.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.18. The business had revenue of $504.00 million during the quarter, compared to analyst estimates of $478.35 million. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. Axon Enterprise’s revenue was up 34.5% compared to the same quarter last year. During the same period last year, the business earned $0.80 EPS. As a group, equities analysts expect that Axon Enterprise, Inc. will post 1.79 EPS for the current fiscal year.

Hedge Funds Weigh In On Axon Enterprise

A number of hedge funds have recently added to or reduced their stakes in the company. Blue Trust Inc. increased its holdings in shares of Axon Enterprise by 987.5% in the 2nd quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 79 shares in the last quarter. Trivant Custom Portfolio Group LLC purchased a new position in Axon Enterprise in the 1st quarter worth about $31,000. Quent Capital LLC lifted its stake in Axon Enterprise by 1,875.0% during the 3rd quarter. Quent Capital LLC now owns 79 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 75 shares during the period. First PREMIER Bank bought a new position in Axon Enterprise during the 1st quarter valued at about $33,000. Finally, Rise Advisors LLC boosted its holdings in shares of Axon Enterprise by 49.0% during the 1st quarter. Rise Advisors LLC now owns 143 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 47 shares during the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Barclays upped their target price on Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Needham & Company LLC restated a “buy” rating and issued a $400.00 price objective on shares of Axon Enterprise in a report on Wednesday, August 7th. JMP Securities upped their target price on Axon Enterprise from $375.00 to $430.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. Craig Hallum raised their target price on Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Finally, Bank of America assumed coverage on Axon Enterprise in a research report on Wednesday, July 17th. They set a “buy” rating and a $380.00 price target on the stock. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, Axon Enterprise has a consensus rating of “Moderate Buy” and an average target price of $365.38.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.